-
American Journal of Obstetrics and... Jun 1999
Topics: Female; Humans; Obstetric Labor, Premature; Pregnancy; Terbutaline; Tocolytic Agents
PubMed: 10368508
DOI: 10.1016/s0002-9378(99)70056-6 -
Drug Development Research May 2022Acute lung injury (ALI), characterized by an acute onset of severe hypoxemia, is a common and devastating syndrome usually triggered by lipopolysaccharide (LPS)...
Acute lung injury (ALI), characterized by an acute onset of severe hypoxemia, is a common and devastating syndrome usually triggered by lipopolysaccharide (LPS) infection from bacteria. This study is intended to explore whether terbutaline can alleviate LPS-induced human pulmonary microvascular endothelial cell (HPMVEC) injury through cAMP/Epac signaling. LPS was utilized to induce ALI in HPMVECs, and after exposure of LPS-induced HPMVECs to terbutaline, the cellular functions including cell viability and apoptosis were measured by cell counting kit-8 and terminal deoxynucleotidyl transferase dUTP nick-end labeling. The protein expression related to cAMP/Epac signaling, apoptosis, and that of tight junction and inflammatory factors were evaluated at the same time. The effects of terbutaline on cellular functions were confirmed again after the addition of antagonists of cAMP and Epac, respectively. The levels of both cAMP and Epac reduced by LPS was concentration-dependently increased by terbutaline. The apoptosis and endothelial cell permeability damage of LPS-induced HPMVECs were enhanced after the addition of KT-5720 and ESI-09. The beneficial effects of terbutaline on alleviating the inflammation and apoptosis in HPMVECs injured by LPS are mediated by cAMP/Epac signaling, and this evidence would demonstrate the potential of terbutaline in the treatment of ALI.
Topics: Acute Lung Injury; Endothelial Cells; Humans; Lipopolysaccharides; Lung; Terbutaline
PubMed: 34846077
DOI: 10.1002/ddr.21901 -
The New England Journal of Medicine Jan 1979
Topics: Aged; Humans; Male; Terbutaline
PubMed: 758605
DOI: 10.1056/nejm197901183000317 -
The Medical Letter on Drugs and... Sep 1975
Topics: Administration, Oral; Asthma; Bronchi; Humans; Muscle, Smooth; Terbutaline
PubMed: 1177814
DOI: No ID Found -
PloS One 2012Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used in pregnant women as a prolonged (beyond 48-72 h) maintenance tocolytic following acute treatment of... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used in pregnant women as a prolonged (beyond 48-72 h) maintenance tocolytic following acute treatment of preterm contractions. The effectiveness and safety of this maintenance tocolysis have not been clearly established. We aimed to systematically evaluate the effectiveness and safety of subcutaneous (SQ) terbutaline infusion by pump for maintenance tocolysis.
METHODOLOGY/PRINCIPAL FINDINGS
MEDLINE, EMBASE, CINAHL, the Cochrane Library, the Centre for Reviews and Dissemination databases, post-marketing surveillance data and grey literature were searched up to April 2011 for relevant experimental and observational studies. Two randomized trials, one nonrandomized trial, and 11 observational studies met inclusion criteria. Non-comparative studies were considered only for pump-related harms. We excluded case-reports but sought FDA summaries of post-marketing surveillance data. Non-English records without an English abstract were excluded. Evidence of low strength from observational studies with risk of bias favored SQ terbutaline pump for the outcomes of delivery at <32 and <37 weeks, mean days of pregnancy prolongation, and neonatal death. Observational studies of medium to high risk of bias also demonstrated benefit for other surrogate outcomes, such as birthweight and neonatal intensive care unit (NICU) admission. Several cases of maternal deaths and maternal cardiovascular events have been reported in patients receiving terbutaline tocolysis.
CONCLUSIONS/SIGNIFICANCE
Although evidence suggests that pump therapy may be beneficial as maintenance tocolysis, our confidence in its validity and reproducibility is low, suggesting that its use should be limited to the research setting. Concerns regarding safety of therapy persist.
Topics: Adult; Birth Weight; Delivery, Obstetric; Female; Gestational Age; Humans; Infant, Newborn; Infusion Pumps; Pregnancy; Premature Birth; Publication Bias; Terbutaline; Treatment Outcome; Young Adult
PubMed: 22363704
DOI: 10.1371/journal.pone.0031679 -
Medicine and Science in Sports and... Jun 2017This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men.
PURPOSE
This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men.
METHODS
Twelve healthy trained men underwent two pharmacokinetic trials comparing single dose (2 mg) and seven consecutive days (2 mg·d) of inhaled terbutaline. After inhalation of terbutaline at each trial, subjects performed 90 min of bike ergometer exercise at 55%-65% of maximal oxygen consumption after which they stayed inactive. Blood and urine samples were collected before and after inhalation of terbutaline. Samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry.
RESULTS
Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day. Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after 7 d of inhalation compared with the first day (274 ± 43 vs 194 ± 33 μg, P ≤ 0.001). These differences were partly attributed to systemic accumulation of terbutaline after consecutive days of inhalation, in that baseline serum and urine samples revealed incomplete elimination of terbutaline.
CONCLUSION
Terbutaline accumulates in serum and urine after consecutive days of inhalation. For doping control purposes, these observations are of relevance if a urine threshold and decision limit is to be introduced for terbutaline on the World Anti-Doping Agency's list of prohibited substances because asthmatic athletes may use their bronchorelievers for consecutive days.
Topics: Administration, Inhalation; Adult; Area Under Curve; Bronchodilator Agents; Drug Administration Schedule; Exercise; Humans; Male; Terbutaline
PubMed: 28072631
DOI: 10.1249/MSS.0000000000001199 -
Lancet (London, England) Oct 1983
Topics: Delayed-Action Preparations; Female; Humans; Middle Aged; Tablets; Terbutaline
PubMed: 6137635
DOI: 10.1016/s0140-6736(83)92333-4 -
Acta Medica Austriaca. Supplement 1979The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways... (Comparative Study)
Comparative Study Review
The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma). In 7 series comparisons were made with other marketed bronchodilators. Airways resistance was measured by whole body plethysmography. In another 3 series the effect on heart rate of terbutaline and other adrenocepter agonists was tested in healthy volunteers. Terbutaline and the adrenoceptor agonists clenbuterol, epinephrine, fenoterol, hexoprenaline, isoprenaline, metaproterenol, reproterol and salbutamol, the vagolytics atropine, ipratropium bromide and AA 22-263, the xanthinederivative theophylline ethylenediamine and one combined substance drug were used.
Topics: Administration, Oral; Adult; Aged; Albuterol; Asthma; Atropine; Clenbuterol; Epinephrine; Female; Fenoterol; Heart Rate; Hexoprenaline; Humans; Injections, Subcutaneous; Ipratropium; Isoproterenol; Male; Middle Aged; Parasympatholytics; Terbutaline; Theophylline
PubMed: 161461
DOI: No ID Found -
Pediatrics Jul 1977The effects of terbutaline, ephedrine, and placebo on the cardiovascular and pulmonary systems have been compared in 24 asthmatic children. Ephedrine and terbutaline... (Clinical Trial)
Clinical Trial Comparative Study
The effects of terbutaline, ephedrine, and placebo on the cardiovascular and pulmonary systems have been compared in 24 asthmatic children. Ephedrine and terbutaline were both found to be effective bronchodilators, with onset of action within 30 minutes. The bronchodilator effect of ephedrine was maintained for three hours, while terbutaline was active for five hours. Terbutaline caused significantly greater improvement in pulmonary functions than did ephedrine. Both terbutaline and ephedrine were associated with clinically insignificant changes in blood pressure and pulse rate. The only significant side effect observed was hand tremor in children receiving terbutaline and this appeared only early in the course of drug treatment. There was no evidence of tolerance to the bronchodilator effect of ephedrine or terbutaline after eight weeks of therapy.
Topics: Adolescent; Asthma; Blood Pressure; Child; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Ephedrine; Humans; Placebos; Pulse; Respiratory Function Tests; Terbutaline
PubMed: 327422
DOI: No ID Found -
Praxis Sep 2018
Comparative Study Randomized Controlled Trial
Topics: Adolescent; Adult; Asthma; Budesonide; Double-Blind Method; Drug Administration Schedule; Female; Formoterol Fumarate; Humans; Male; Terbutaline; Young Adult
PubMed: 30227794
DOI: 10.1024/1661-8157/a003056